A Registry of Participants With Prostate Cancer in Asia

Status Completed

Clinical Trial Summary

The purpose of this study is to document prostate cancer (PC) management including diagnosis, prognosis, treatment, and care in real-world practice.

Clinical Trial Description

This is a multicenter (when more than one hospital or medical school team work on a medical research study), prospective (observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group), longitudinal, observational registry (clinical study in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions [as in an interventional study])of PC participants. The following 3 participant cohorts will be enrolled: high-risk localized PC, non-metastatic biochemically recurrent PC, and metastatic PC. This is an observational study and treatment decisions and clinical management of participants will follow routine clinical practice. Medical care given to participants will not be influenced by participation in the study. Enrolled participants will be prospectively followed throughout their course of treatment, during which data on PC treatment, clinical progression, and outcomes (including death) will be collected. At the end of registry medical resource utilization (MRU) will also be collected. The maximum observational period will be 5 years. Safety will be monitored throughout the study for participants being treated with JNJ products. ;

Study Design

Related Conditions & MeSH terms

Prostatic Neoplasms

Clinical Trial Details

NCT number	NCT02546908
Study type	Observational [Patient Registry]
Source	Janssen Research & Development, LLC
Contact
Status	Completed
Phase
Start date	September 9, 2015
Completion date	September 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04964271` - Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
Completed	`NCT04838626` - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection	Phase 2/Phase 3
Recruiting	`NCT03101176` - Multiparametric Ultrasound Imaging in Prostate Cancer	N/A
Completed	`NCT01683994` - Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer	Phase 1/Phase 2
Completed	`NCT04838613` - Study of Diagnostic Performance of [18F]CTT1057 in BCR	Phase 3
Completed	`NCT02364531` - A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Completed	`NCT01929655` - Japanese BAY88-8223 Monotherapy Phase II Study	Phase 2
Active, not recruiting	`NCT05022849` - A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants	Phase 1
Completed	`NCT03261999` - Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer	Phase 3
Terminated	`NCT04907227` - Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension	Phase 3
Active, not recruiting	`NCT03587285` - A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer	Phase 1/Phase 2
Completed	`NCT02217566` - Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy	Phase 2
Not yet recruiting	`NCT04101305` - Measurement of Circulating Tumor Cells in Prostate Cancer
Active, not recruiting	`NCT02950064` - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations	Phase 1
Terminated	`NCT03066154` - Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer	Phase 1
Withdrawn	`NCT02905201` - A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	N/A
Completed	`NCT02692976` - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients	Phase 2
Terminated	`NCT01420965` - Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer	Phase 2
Completed	`NCT01441713` - Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer	N/A
Terminated	`NCT01450683` - Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy	Phase 2